Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

FDA Clears Aro Biotherapeutics' siRNA Drug IND for Late-Onset Pompe Disease ...

Consider that since December, Vertex Pharmaceuticals has earned approval for two brand-new medicines: Alyftrek and Journavx. The former is the biotech's latest cystic fibrosis (CF) medicine.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

“2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch ...

Optum Rx has eliminated reauthorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior authorizations. Optum Rx is eliminating reauthorization on almost 70 drugs for ...

On March 7, 2025, the company received approval from the UK’s Medicines and Healthcare products Regulatory Agency for ALYFTREK, a once-daily treatment for cystic fibrosis in patients aged six ...